Dishman Carbogen Amcis Limited Logo

Dishman Carbogen Amcis Limited

DCAL.NS

(1.8)
Stock Price

191,29 INR

-0.87% ROA

-3.55% ROE

-65.63x PER

Market Cap.

29.988.048.910,00 INR

39.99% DER

0% Yield

-5.98% NPM

Dishman Carbogen Amcis Limited Stock Analysis

Dishman Carbogen Amcis Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Dishman Carbogen Amcis Limited Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (0.46x) suggests it's undervalued, making it an attractive opportunity for investors.

2 DER

The stock has a minimal amount of debt (33%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Assets Growth

With a track record of consistent revenue growth in the past five years, this company presents a compelling opportunity.

4 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock appears undervalued (11.200), presenting an attractive investment chance with its intrinsic value surpassing the current market price.

5 ROE

The stock's ROE indicates a negative return (-0.53%) on shareholders' equity, suggesting poor financial performance.

6 ROA

The stock's ROA (-0.61%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

7 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

8 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

9 Graham Number

The Graham number calculation reveals that this company's stock price is potentially inflated, implying that it may not be a desirable investment option.

10 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

11 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

Dishman Carbogen Amcis Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Dishman Carbogen Amcis Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Sell
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Dishman Carbogen Amcis Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Dishman Carbogen Amcis Limited Revenue
Year Revenue Growth
2005 2.774.398.000
2006 5.785.720.000 52.05%
2007 8.030.762.000 27.96%
2008 10.623.578.000 24.41%
2009 9.153.574.000 -16.06%
2010 9.908.440.000 7.62%
2011 11.241.117.000 11.86%
2012 12.722.178.000 11.64%
2013 13.852.482.000 8.16%
2014 15.752.052.000 12.06%
2015 15.960.500.000 1.31%
2016 17.136.900.000 6.86%
2017 16.946.400.000 -1.12%
2018 20.585.900.000 17.68%
2019 20.436.000.000 -0.73%
2020 19.120.300.000 -6.88%
2021 21.406.800.000 10.68%
2022 24.129.200.000 11.28%
2023 23.463.600.000 -2.84%
2023 26.157.700.000 10.3%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Dishman Carbogen Amcis Limited Research and Development Expenses
Year Research and Development Expenses Growth
2005 0
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 32.422.000 100%
2012 2.708.000 -1097.27%
2013 11.499.000 76.45%
2014 5.728.000 -100.75%
2015 116.600.000 95.09%
2016 52.900.000 -120.42%
2017 52.400.000 -0.95%
2018 137.700.000 61.95%
2019 215.500.000 36.1%
2020 65.000.000 -231.54%
2021 139.000.000 53.24%
2022 172.900.000 19.61%
2023 0 0%
2023 60.300.000 100%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Dishman Carbogen Amcis Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
2005 262.858.000
2006 689.651.000 61.89%
2007 841.959.000 18.09%
2008 1.244.610.000 32.35%
2009 1.001.576.000 -24.27%
2010 987.419.000 -1.43%
2011 1.322.831.000 25.36%
2012 265.464.000 -398.31%
2013 321.249.000 17.37%
2014 405.860.000 20.85%
2015 493.600.000 17.78%
2016 613.600.000 19.56%
2017 495.700.000 -23.78%
2018 731.300.000 32.22%
2019 557.600.000 -31.15%
2020 630.900.000 11.62%
2021 721.600.000 12.57%
2022 1.003.400.000 28.08%
2023 0 0%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Dishman Carbogen Amcis Limited EBITDA
Year EBITDA Growth
2005 650.119.000
2006 1.144.359.000 43.19%
2007 1.447.201.000 20.93%
2008 2.617.028.000 44.7%
2009 2.040.018.000 -28.28%
2010 2.024.428.000 -0.77%
2011 2.467.092.000 17.94%
2012 3.003.517.000 17.86%
2013 3.402.814.000 11.73%
2014 3.887.728.000 12.47%
2015 4.085.700.000 4.85%
2016 4.722.600.000 13.49%
2017 4.832.800.000 2.28%
2018 5.878.900.000 17.79%
2019 5.604.700.000 -4.89%
2020 3.069.300.000 -82.61%
2021 3.543.600.000 13.38%
2022 3.599.700.000 1.56%
2023 2.772.800.000 -29.82%
2023 2.865.000.000 3.22%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Dishman Carbogen Amcis Limited Gross Profit
Year Gross Profit Growth
2005 1.254.020.000
2006 3.250.110.000 61.42%
2007 4.524.642.000 28.17%
2008 6.589.322.000 31.33%
2009 5.579.931.000 -18.09%
2010 5.413.610.000 -3.07%
2011 7.395.816.000 26.8%
2012 8.921.198.000 17.1%
2013 10.071.539.000 11.42%
2014 10.356.499.000 2.75%
2015 12.501.700.000 17.16%
2016 13.761.200.000 9.15%
2017 13.425.900.000 -2.5%
2018 16.390.700.000 18.09%
2019 15.928.700.000 -2.9%
2020 14.279.400.000 -11.55%
2021 16.818.000.000 15.09%
2022 19.015.100.000 11.55%
2023 18.089.600.000 -5.12%
2023 4.903.800.000 -268.89%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Dishman Carbogen Amcis Limited Net Profit
Year Net Profit Growth
2005 508.445.000
2006 917.090.000 44.56%
2007 1.197.068.000 23.39%
2008 1.461.911.000 18.12%
2009 1.173.750.000 -24.55%
2010 813.443.000 -44.29%
2011 567.585.000 -43.32%
2012 1.002.938.000 43.41%
2013 1.092.722.000 8.22%
2014 1.198.090.000 8.79%
2015 1.711.100.000 29.98%
2016 1.454.300.000 -17.66%
2017 1.545.700.000 5.91%
2018 2.103.300.000 26.51%
2019 1.585.100.000 -32.69%
2020 -1.651.300.000 195.99%
2021 180.100.000 1016.88%
2022 -298.000.000 160.44%
2023 -1.636.000.000 81.78%
2023 -1.534.500.000 -6.61%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Dishman Carbogen Amcis Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2005 4
2006 7 50%
2007 8 14.29%
2008 9 22.22%
2009 7 -28.57%
2010 5 -75%
2011 4 -33.33%
2012 6 50%
2013 7 0%
2014 7 14.29%
2015 11 30%
2016 9 -11.11%
2017 10 0%
2018 13 30.77%
2019 10 -44.44%
2020 -11 190%
2021 1 1100%
2022 -2 200%
2023 -10 90%
2023 -10 -11.11%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Dishman Carbogen Amcis Limited Free Cashflow
Year Free Cashflow Growth
2005 -704.333.000
2006 -3.750.203.000 81.22%
2007 -2.205.565.000 -70.03%
2008 -428.874.000 -414.27%
2009 -36.256.000 -1082.9%
2010 -378.361.000 90.42%
2011 586.635.000 164.5%
2012 279.550.000 -109.85%
2013 453.019.000 38.29%
2014 1.303.664.000 65.25%
2015 1.547.700.000 15.77%
2016 1.546.900.000 -0.05%
2017 99.900.000 -1448.45%
2018 -260.700.000 138.32%
2019 1.765.800.000 114.76%
2020 1.474.000.000 -19.8%
2021 -1.089.500.000 235.29%
2022 -3.537.200.000 69.2%
2023 0 0%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Dishman Carbogen Amcis Limited Operating Cashflow
Year Operating Cashflow Growth
2005 154.023.000
2006 427.317.000 63.96%
2007 494.353.000 13.56%
2008 1.317.642.000 62.48%
2009 3.022.103.000 56.4%
2010 2.054.835.000 -47.07%
2011 1.535.763.000 -33.8%
2012 1.373.193.000 -11.84%
2013 3.445.023.000 60.14%
2014 2.857.953.000 -20.54%
2015 2.786.400.000 -2.57%
2016 3.026.500.000 7.93%
2017 2.264.400.000 -33.66%
2018 2.820.400.000 19.71%
2019 5.851.400.000 51.8%
2020 5.134.300.000 -13.97%
2021 3.548.500.000 -44.69%
2022 2.203.400.000 -61.05%
2023 0 0%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Dishman Carbogen Amcis Limited Capital Expenditure
Year Capital Expenditure Growth
2005 858.356.000
2006 4.177.520.000 79.45%
2007 2.699.918.000 -54.73%
2008 1.746.516.000 -54.59%
2009 3.058.359.000 42.89%
2010 2.433.196.000 -25.69%
2011 949.128.000 -156.36%
2012 1.093.643.000 13.21%
2013 2.992.004.000 63.45%
2014 1.554.289.000 -92.5%
2015 1.238.700.000 -25.48%
2016 1.479.600.000 16.28%
2017 2.164.500.000 31.64%
2018 3.081.100.000 29.75%
2019 4.085.600.000 24.59%
2020 3.660.300.000 -11.62%
2021 4.638.000.000 21.08%
2022 5.740.600.000 19.21%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Dishman Carbogen Amcis Limited Equity
Year Equity Growth
2005 1.885.213.000
2006 3.183.301.000 40.78%
2007 5.734.737.000 44.49%
2008 7.043.914.000 18.59%
2009 7.842.611.000 10.18%
2010 8.791.567.000 10.79%
2011 9.319.892.000 5.67%
2012 10.308.027.000 9.59%
2013 11.772.046.000 12.44%
2014 12.377.850.000 4.89%
2015 14.515.500.000 14.73%
2016 48.139.800.000 69.85%
2017 51.073.300.000 5.74%
2018 53.790.900.000 5.05%
2019 57.376.900.000 6.25%
2020 56.988.200.000 -0.68%
2021 55.489.400.000 -2.7%
2022 58.096.700.000 4.49%
2023 57.708.300.000 -0.67%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Dishman Carbogen Amcis Limited Assets
Year Assets Growth
2005 5.955.804.000
2006 11.608.630.000 48.7%
2007 14.935.972.000 22.28%
2008 16.891.596.000 11.58%
2009 17.923.267.000 5.76%
2010 20.822.853.000 13.93%
2011 22.586.762.000 7.81%
2012 22.911.117.000 1.42%
2013 25.541.994.000 10.3%
2014 28.089.357.000 9.07%
2015 29.805.300.000 5.76%
2016 65.934.300.000 54.8%
2017 71.764.800.000 8.12%
2018 73.284.600.000 2.07%
2019 82.224.200.000 10.87%
2020 83.246.000.000 1.23%
2021 86.374.500.000 3.62%
2022 94.535.000.000 8.63%
2023 95.011.200.000 0.5%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Dishman Carbogen Amcis Limited Liabilities
Year Liabilities Growth
2005 4.070.591.000
2006 8.425.329.000 51.69%
2007 9.201.235.000 8.43%
2008 9.847.682.000 6.56%
2009 10.080.656.000 2.31%
2010 12.031.286.000 16.21%
2011 13.266.870.000 9.31%
2012 12.603.090.000 -5.27%
2013 13.769.948.000 8.47%
2014 15.711.507.000 12.36%
2015 15.285.400.000 -2.79%
2016 17.794.500.000 14.1%
2017 20.691.500.000 14%
2018 19.493.700.000 -6.14%
2019 24.847.300.000 21.55%
2020 26.257.800.000 5.37%
2021 30.885.100.000 14.98%
2022 36.438.300.000 15.24%
2023 37.302.900.000 2.32%

Dishman Carbogen Amcis Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
163.9
Net Income per Share
-3.04
Price to Earning Ratio
-65.63x
Price To Sales Ratio
1.17x
POCF Ratio
0
PFCF Ratio
0
Price to Book Ratio
0.54
EV to Sales
1.99
EV Over EBITDA
13.61
EV to Operating CashFlow
0
EV to FreeCashFlow
0
Earnings Yield
-0.02
FreeCashFlow Yield
0
Market Cap
29,99 Bil.
Enterprise Value
51,19 Bil.
Graham Number
158.75
Graham NetNet
-157.21

Income Statement Metrics

Net Income per Share
-3.04
Income Quality
0
ROE
-0.02
Return On Assets
0
Return On Capital Employed
0
Net Income per EBT
0.96
EBT Per Ebit
-2.46
Ebit per Revenue
0.03
Effective Tax Rate
0.04

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.62
Operating Profit Margin
0.03
Pretax Profit Margin
-0.06
Net Profit Margin
-0.06

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0
Free CashFlow per Share
0
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
0.01
Return on Tangible Assets
-0.01
Days Sales Outstanding
67.51
Days Payables Outstanding
137.54
Days of Inventory on Hand
559.24
Receivables Turnover
5.41
Payables Turnover
2.65
Inventory Turnover
0.65
Capex per Share
0

Balance Sheet

Cash per Share
30,92
Book Value per Share
368,26
Tangible Book Value per Share
111.16
Shareholders Equity per Share
368.26
Interest Debt per Share
153.81
Debt to Equity
0.4
Debt to Assets
0.24
Net Debt to EBITDA
5.64
Current Ratio
1.04
Tangible Asset Value
17,42 Bil.
Net Current Asset Value
-17,67 Bil.
Invested Capital
0.4
Working Capital
0,81 Bil.
Intangibles to Total Assets
0.42
Average Receivables
2,38 Bil.
Average Payables
1,05 Bil.
Average Inventory
4258450000
Debt to Market Cap
0.77

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Dishman Carbogen Amcis Limited Dividends
Year Dividends Growth
2004 2
2005 3 0%
2006 1 0%
2007 1 100%
2008 1 0%
2009 1 0%
2010 1 0%
2011 1 0%
2012 1 0%
2013 1 0%
2014 1 0%
2015 2 50%
2016 2 0%
2017 1 -100%
2019 0 0%

Dishman Carbogen Amcis Limited Profile

About Dishman Carbogen Amcis Limited

Dishman Carbogen Amcis Limited provides contract research and manufacturing services to the pharmaceutical industry worldwide. The company operates through Contract Research and Manufacturing Services and Marketable Molecules segments. It also manufactures and supplies bulk drugs, intermediates, phase transfer catalysts, quaternary ammonium compounds, phosphoranes, wittig reagents, vitamin D products, fine chemicals, hand and body wash, sanitisers, antiseptics, and various pharmaceutical and cosmetic-related products, as well as generic and highly potent active pharmaceutical ingredients. The company was incorporated in 1983 and is headquartered in Ahmedabad, India. Dishman Carbogen Amcis Limited is a subsidiary of Adimans Technologies LLP.

CEO
Mr. Pascal Villemagne
Employee
1.295
Address
Dishman Corporate House
Ahmedabad, 380058

Dishman Carbogen Amcis Limited Executives & BODs

Dishman Carbogen Amcis Limited Executives & BODs
# Name Age
1 Mr. Paolo Armanino
Chief Operating Officer of Indian Operations
70
2 Mr. Dharmesh Desai
GM of Secretarial & Legal
70
3 Ms. Deohooti Janmejay Vyas
Whole Time Director
70
4 Dieter Thuer
Global Head of HR
70
5 Dr. Himani S. Dhotre
Chief Executive Officer of Projects & Operations
70
6 Ms. Shrima Gaurangbhai Dave
Compliance Officer & Company Secretary
70
7 Mr. Harshil R. Dalal
Global Chief Financial Officer
70
8 Mr. Pascal Villemagne
Chief Executive Officer of CARBOGEN AMCIS
70
9 Mr. . HUZIFA
Sales Manager
70
10 Mr. Arpit Janmejay Vyas
Global MD & Director
70

Dishman Carbogen Amcis Limited Competitors

Caplin Point Laboratories Limited Logo
Caplin Point Laboratories Limited

CAPLIPOINT.NS

(4.2)
Shilpa Medicare Limited Logo
Shilpa Medicare Limited

SHILPAMED.NS

(1.5)
Bliss GVS Pharma Limited Logo
Bliss GVS Pharma Limited

BLISSGVS.NS

(3.2)
Indoco Remedies Limited Logo
Indoco Remedies Limited

INDOCO.NS

(3.2)